Frequently asked questions about community-acquired pneumonia
1) When should community-acquired pneumonia be suspected?
Community-acquired pneumonia should be suspected in the presence of an acute or subacute onset of fever, cough with or without sputum production, dyspnoea, tachypnoea, pleuritic chest pain or suggestive auscultatory findings. In older adults, the presentation may be non-specific, with weakness, confusion, anorexia or functional decline.
2) Is chest radiography always required?
No. In the outpatient setting, chest radiography may not be mandatory when clinical suspicion is high and there are no severity criteria. It should be considered when there is diagnostic uncertainty, an unfavourable clinical course, risk of complications, suspected malignancy or a need to exclude differential diagnoses.
3) Which signs suggest the need for hospital referral?
Hospital referral should be considered in the presence of SpO₂ <94%, haemodynamic instability, confusion, an elevated respiratory rate, inability to take oral medication, pregnancy, lack of adequate support at home, relevant comorbidities or clinical deterioration despite initial treatment.
4) What is the role of CRB-65?
CRB-65 helps stratify pneumonia severity using four variables: confusion, respiratory rate ≥30/min, systolic blood pressure <90 mmHg or diastolic blood pressure ≤60 mmHg, and age ≥65 years. It should be used together with clinical judgement, peripheral oxygen saturation, comorbidities and the patient’s social circumstances.
5) Does a CRB-65 score of 0 always allow outpatient treatment?
In most cases, yes, provided the patient is clinically stable, has adequate peripheral oxygen saturation, can take oral treatment and has sufficient support at home. However, the decision should be individualised, particularly in frail older adults, immunocompromised patients or those with multiple comorbidities.
6) What is the first-line antibiotic treatment in patients without relevant comorbidities?
In adults without relevant comorbidities and without recent antibiotic exposure, amoxicillin monotherapy is frequently a first-line option. Alternatives such as azithromycin, clarithromycin or doxycycline may be considered in specific situations, including allergy, intolerance or suspected atypical pathogens.
7) When should combination antibiotic therapy be considered?
The combination of amoxicillin with a macrolide or doxycycline may be considered in patients with relevant comorbidities, a greater risk of an unfavourable course or a need for coverage of atypical pathogens. The decision should take into account severity, local epidemiology, previous antibiotic exposure and the risk of adverse effects.
8) When should respiratory fluoroquinolones be used?
Respiratory fluoroquinolones, such as levofloxacin or moxifloxacin, should be reserved for specific situations, including allergy or intolerance to alternatives, treatment failure or inability to use first-line regimens. Their use should be cautious because of the risk of adverse effects and their impact on antimicrobial stewardship.
9) When should clinical reassessment take place?
Clinical reassessment should generally take place after 48–72 hours of treatment, or earlier if the patient deteriorates. Failure to improve should prompt review of the diagnosis, treatment adherence, dosage, possible complications, antimicrobial resistance or alternative diagnoses.
10) When should chest radiography be repeated after treatment?
Repeat chest radiography should be considered if the clinical course is unfavourable, symptoms persist or a complication is suspected. It may also be indicated approximately 6 weeks after diagnosis in patients at increased risk of malignancy, particularly smokers, people over 50 years of age or those with slow resolution of pneumonia.
